Given that Johannessen et al. 24 identified TPL2 as a MAPK pathway agonist that activates MEK independent of RAF signaling and drives resistance to RAF inhibition in melanoma, we hypothesized that TPL2 might be upregulated in B16BR cells. Here, MAP2K7 is linked to melanoma.